Guillain-Barré syndrome

Current Neurology and Neuroscience Reports

Volumn 7, Issue 1, 2007, Pages 57-62

  Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; EPITOPE; GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GM1; GLYCOLIPID; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; ION CHANNEL; LIPOOLIGOSACCHARIDE; METHYLPREDNISOLONE; PROTEIN SUBUNIT; SODIUM CHANNEL BLOCKING AGENT;

ACUTE DISEASE; BACTERIAL CELL WALL; CAMPYLOBACTER JEJUNI; CLINICAL TRIAL; DEMYELINATING NEUROPATHY; ELECTRODIAGNOSIS; GENETIC POLYMORPHISM; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; META ANALYSIS; MOLECULAR BIOLOGY; MORBIDITY; MOTOR NERVE; MOTOR NEUROPATHY; NERVE BLOCK; NERVE FIBER DEGENERATION; NERVE FIBER MEMBRANE; NONHUMAN; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

GUILLAIN-BARRE SYNDROME; HUMANS;

EID: 33846695395     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0022-6     Document Type: Review

References (39)

1. Griffin JW, Li CY, Ho TW, et al.: Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996, 39:17-28.
2. Kuwabara S: Guillain-Barré syndrome. Epidemiology, pathophysiology and management. Drugs 2004, 64:597-610.
3. Hughes RA, Corblath DR: Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
4. Ho TW, Mishu B, Li CY, et al.: Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597-605.
5. Ogawara K, Kuwabara S, Mori M, et al.: Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000, 48:624-631.
6. Yuki N: Carbonhydrate mimicry: a new paradigm of autoimmune diseases. Curr Opin Immunol 2005, 17:577-582.
7. Hadden RD, Cornblath DR, Hughes RA, et al.: Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998, 44:780-788.
8. Jacobs BC, Rothbarth PH, van der Meché FG, et al.: The spectrum of antecedent infections in Guillain-Barré syndrome. A case control study. Neurology 1998, 51:1110-1115.
9. Hughes RA, Rees JH: Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis 1997, 175(Suppl): S92-S100.
10. Kuwabara S, Ogawara K, Misawa S, et al.: Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome? Neurology 2004, 63:529-533.
11. Yuki N, Susuki K, Koga M, et al.: Carbonhydrate mimicry between human ganglioside GM1 asnd Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 2004, 101:11404-11409.
12. Yuki N, Yamada M, Koga M, et al.: Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001, 49:712-720.
13. Susuki K, Nishimoto Y, Yamada M, et al.: Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann Neurol 2003, 54:383-388.
14. Gilbert M, Karwaski MF, Bernatchez S, et al.: The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni: biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 2002, 277:327-337.
15. Godschalk PC, Heikema AP, Gilbert M, et al.: The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J Clin Invest 2004, 14:1659-1665.
16. Koga M, Takahashi M, Masuda M, et al.: Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005, 65:1376-1381.
17. Olsson Y: Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol 1990, 5:265-311.
18. Bromberg M, Albers JW: Patterns of sensory nerve conduction abnormalities in demyelinating anad axonal peripheral nerve disorders. Muscle Nerve 1993, 16:262-266.
19. Kuwabara S, Ogawara K, Misawa S, et al.: Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002, 72:37-42.
20. Kuwabara S, Ogawara K, Misawa S, et al.: Sensory nerve conduction in demyelinating and axonal Guillain-Barré syndromes. Eur Neurol 2004, 51:196-198.
21. Kuwabara S, Yuki N, Koga M, et al.: IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998, 44:202-208.
22. Hiraga A, Kuwabara S, Ogawara K, et al.: Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome. Neurology 2005, 64:856-860.
23. Kuwabara S, Ogawara K, Sung JY, et al.: Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Ann Neurol 2002, 52:180-187.
24. Kuwabara S, Bostock H, Ogawara K, et al.: The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. Muscle Nerve 2003, 28:683-689.
25. Kiernan MC, Isbister GK, Lin CS, et al.: Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005, 57:339-348.
26. Pedraza L, Huang J, Colman DR: Organizing principles of the axoglial apparatus. Neuron 2001, 30:335-344.
27. Melendez-Vasquez CV, Rios J, Zanazzi G, et al.: Nodes of Ranvier form in association with ezrin-radixin-moesin (ERM)-positive Schwann cell processes. Proc Natl Acad Sci U S A 2001, 98:1235-1240.
28. Ishubashi T, Dupree JL, Ikenaka K, et al.: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J Neurosci 2002, 22:6507-6514.
29. Hughes RA, Swan AV, van Koningsveld R, et al.: Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006, 19:CD001446.
30. Rich MM, Pinter MJ: Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001, 50:26-33.
31. Raphael JC, Chevret S, Hughes RA, et al.: Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2001, CD001798.
32. Hughes RA, Raphael JC, Swan AV, et al.: Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2004, CD002063.
33. Hadden RD, Karch H, Hartung HP, et al.: Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001, 56:758-765.
34. Kuwabara S, Mori M, Ogawara K, et al.: Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001, 24:54-58.
35. Wollinsky KH, Hulser PJ, Brinkmeier H, et al.: CFS filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2002, 57:774-780.
36. Schaller B, Radziwill AJ, Steck AJ: Successful treatment of Guillain-Barré syndrome with combined administration of Interferon-b-1a and intravenous immunoglobulin. Eur Neurol 2001, 46:167-168.
37. Miyamoto K, Oka N, Kawasaki T, et al.: New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 2002, 25:280-282.
38. Bechtold DA, Yue X, Evans RM, et al.: Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecanamide. Brain 2005, 128:18-28.
39. Rees JH, Thompson RD, Smeeton NC, et al.: Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998, 64:74-77.